University of California San Francisco
Give to UCSFUCSF scientists have engineered human immune cells that can precisely locate diseased cells anywhere in the body and execute a wide range of customizable responses, including the delivery of drugs or other therapeutic payloads directly to tumors or other unhealthy tissues.
Gut microbes present in some one-month-old infants predict a three-fold higher risk of developing allergic reactions by age two and asthma by age four.
The abundance of a subtype of white blood cells in melanoma tumors can predict whether or not patients will respond to a form of cancer immunotherapy known as checkpoint blockade, according to a new study led by UCSF researchers and physicians.
A new study led by UCSF scientists shows that a bacterium commonly found in the human gut is overrepresented in patients with a rare, often disabling autoimmune disease known as neuromyelitis optica.
Zika virus can infect numerous cell types in the human placenta and amniotic sac, according to researchers at UCSF and UC Berkeley who show in a new paper how the virus travels from a pregnant woman to her fetus.
Using advanced imaging technology that allowed them to spy on interactions among cells in the lymph nodes of living mice, a research team led by UCSF scientists has identified a cell that is a key player in mounting the immune system’s defense against cancer.
A previously unidentifiable type of low-grade inflammation may explain why common anti-inflammatory drugs such as aspirin have shown promise against some types of cancer – even when patients don’t display typical signs of inflammation.
UC San Francisco researchers have shed light on how the immune system of a fetus can run amok, triggering inflammation in the developing intestines that protrude outside of the body through a hole beside the belly button.
With one drug to shut down its progression and another to undo its damage, plus a worldwide effort stalking the origins of multiple sclerosis, MS doesn’t stand a chance.
Oncologist Lawrence Fong is leading UCSF’s newly launched Cancer Immunotherapy Program, a clinic and laboratory dedicated to developing and studying cutting-edge immunotherapy treatments.
Renowned UCSF immunologist Jeffrey Bluestone, PhD, has been named president and CEO of the Parker Institute for Cancer Immunotherapy, a national initiative launched with a $250 million grant from The Parker Foundation, established by Silicon Valley entrepreneur Sean Parker.